AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP has initiated an investigation into Aquestive Therapeutics, Inc. following a significant drop in its stock price due to FDA deficiencies identified in its New Drug Application for Anaphylm, raising concerns about the drug's approvability [1] Company Summary - Aquestive Therapeutics, Inc. (NASDAQ: AQST) experienced a stock price decline of approximately 40% intraday after the FDA disclosed deficiencies in its New Drug Application for Anaphylm, an experimental treatment for severe allergic reactions [1] - The FDA's findings prevent discussions regarding labeling and post-marketing requirements, which raises doubts about the application's approvability ahead of the January 31, 2026, PDUFA action date [1] Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses [1] - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1]